Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Jörg Kaiser

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3980-4340; OpenAlex author ID A5029490503. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
75
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 4 papers

Papers 16

  1. ChatGPT vs. surgeons on pancreatic cancer queries: accuracy & empathy evaluated by patients and experts. Co-author DOI 10.1016/j.hpb.2024.11.012↗
  2. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  3. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  4. Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y↗
  5. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  6. Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection of IPMN-associated pancreatic adenocarcin… Co-author DOI 10.1016/j.ejso.2022.08.003↗
  7. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade. Co-author DOI 10.1016/j.ejso.2021.07.020↗
  8. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy. Co-author DOI 10.1016/j.ejso.2021.12.009↗
  9. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? Co-author DOI 10.1097/sla.0000000000004147↗
  10. A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004845↗
  11. Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2021.02.011↗
  12. Diffusion Kurtosis Imaging-A Superior Approach to Assess Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12061656↗
  13. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  14. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  15. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Co-author DOI 10.1002/bjs.10842↗
  16. Extended Pancreatectomy: Does It Have a Role in the Contemporary Management of Pancreatic Adenocarcinoma? Co-author DOI 10.1159/000478539↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Markus Wolfgang Büchler · 11 shared papers, 2017–2025 · strength 1.56
  2. Thilo Hackert · 10 shared papers, 2017–2024 · strength 1.31
  3. Thomas P. Hank · 8 shared papers, 2018–2025 · strength 1.13
  4. Oliver Strobel · 7 shared papers, 2018–2023 · strength 0.95
  5. Martin Loos · 4 shared papers, 2024–2025 · strength 0.72
  6. Lois A. Daamen · 3 shared papers, 2024–2025 · strength 0.49
  7. Izaak Quintus Molenaar · 3 shared papers, 2024–2025 · strength 0.49
  8. Joseph R. Habib · 3 shared papers, 2024–2025 · strength 0.49
  9. Christopher L. Wolfgang · 3 shared papers, 2024–2025 · strength 0.49
  10. Benedict Kinny‐Köster · 3 shared papers, 2024–2025 · strength 0.49
  11. Marc G. Besselink · 3 shared papers, 2024–2025 · strength 0.49
  12. Ammar A. Javed · 3 shared papers, 2024–2025 · strength 0.49
  13. Giovanni Marchegiani · 3 shared papers, 2022–2025 · strength 0.43
  14. Anna‐Katharina König · 3 shared papers, 2022 · strength 0.41
  15. Daniel Brock Hewitt · 2 shared papers, 2025 · strength 0.36
  16. Adrian Theophil Billeter · 2 shared papers, 2025 · strength 0.36
  17. Ingmar Florin Rompen · 2 shared papers, 2025 · strength 0.36
  18. Brady A. Campbell · 2 shared papers, 2025 · strength 0.36
  19. Paul C. M. Andel · 2 shared papers, 2025 · strength 0.36
  20. Greg D. Sacks · 2 shared papers, 2025 · strength 0.36
  21. Matthias M. Gaida · 3 shared papers, 2020–2022 · strength 0.36
  22. Willem Niesen · 3 shared papers, 2018–2022 · strength 0.34
  23. Carl-Stephan Leonhardt · 2 shared papers, 2022–2023 · strength 0.33
  24. Jin Peng He · 2 shared papers, 2024–2025 · strength 0.32
  25. Kelly J. Lafaro · 2 shared papers, 2024–2025 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.